POST-TEST
Real World Oncology Rounds: Current Concepts and Recent Advances in Oncology | February 2021
THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.
1. The Phase III ECHELON-1 trial 5. Which of the following drug types best comparing brentuximab vedotin (A) with describes the mechanism of action of doxorubicin/vinblastine/dacarbazine the recently FDA-approved agent selper- (AVD) to bleomycin with AVD (ABVD) catinib for patients with metastatic for patients with previously untreated NSCLC? Stage III/IV classical Hodgkin lymphoma a. ALK inhibitor demonstrated which of the following b. EGFR inhibitor progression-free survival outcomes at c. HER2 inhibitor 5 years of follow-up? d. MET inhibitor a. No significant improvement with A + AVD compared to ABVD e. RET inhibitor b. Significant improvement with f. ROS1 inhibitor A + AVD compared to ABVD 6. Which of the following regimens recently 2. Which of the following drug types best received FDA approval for the treatment describes the mechanism of action of of metastatic colorectal cancer with a belantamab mafodotin, which is FDA BRAF V600E mutation on the basis of approved for patients with relapsed/ data from the BEACON CRC study? refractory multiple myeloma? a. Dabrafenib/trametinib a. Proteasome inhibitor b. Vemurafenib/cobimetinib b. CAR T-cell therapy c. Encorafenib/cetuximab c. Anti-BCMA targeted antibody 7. In the recent presentation at ESMO 3. On the basis of results from the 2020 by Kelly and colleagues, which Phase II KEYNOTE-057 trial, pembro- of the following outcomes was reported lizumab is approved for which patients from the Phase III CheckMate 577 with BCG-unresponsive, high-risk trial of adjuvant nivolumab or placebo non-muscle-invasive bladder cancer? for patients with resected Stage II or III esophageal or gastroesophageal a. All patients with carcinoma in situ cancer who had received neoadjuvant b. Patients with carcinoma in situ chemoradiation therapy? who are ineligible for or refuse a. A significant improvement in cystectomy disease-free survival with nivolumab 4. Interim results of the Phase II DESTINY- b. No significant difference in Lung01 study evaluating the antibody- disease-free survival between the drug conjugate trastuzumab deruxtecan study arms demonstrated promising clinical activity with a high objective response rate 8. Which of the following adverse events is and durable responses among patients associated with trastuzumab deruxtecan? with nonsquamous non-small cell lung a. New secondary cancer cancer (NSCLC) with which targetable b. Ocular toxicity mutations? c. Interstitial lung disease a. KRAS G12C mutations only b. EGFR mutations only c. HER2 mutations only d. MET exon 14 skipping mutations only e. Both EGFR and HER2 mutations QID 3277 POST-TEST
Real World Oncology Rounds: Current Concepts and Recent Advances in Oncology | February 2021
THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.
9. What did the Phase III HER2CLIMB 10. Which of the following drug types best trial demonstrate regarding the activity describes the mechanism of action of of tucatinib versus placebo in combi- magrolimab? nation with trastuzumab/capecitabine a. Hypomethylating agent in patients with previously treated b. Bcl-2 inhibitor HER2-positive breast cancer and brain c. Anti-CD47 monoclonal antibody metastases? a. Tucatinib is not active in patients with brain metastases b. Tucatinib is significantly active in patients with brain metastases
QID 3277